News

Video

Intracranial Efficacy of Datopotamab Deruxtecan in Patients With Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From TROPION-Lung05

Author(s):

Charu Aggarwal, MD, MPH

Tropion-Lung05 (NCT04484142) is a phase 2, multicenter, single-arm, open-label study evaluating Dato-DXd in patients with advanced/metastatic NSCLC with actionable genomic alterations who have progressed on or after targeted therapy and platinum-based CT.

Related Videos
RLY-2608
Ewa Kalinka, MD, PhD
BOVen
RMC-6236
LTE-1 ASPEN LTFU
Data from an Ongoing Phase 1/1b Study BGB-11417-101
Related Content
Alexander Watson, MD, DPhil, FRCPC
January 23rd 2025

Driver-Positive Tumor Frequency Decreases With Increasing Copy Number Gain in NSCLC

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

TKIs in Second-Line HER2-Mutant NSCLC | Image Credit: © Axel Kock – stock.adobe.com
January 21st 2025

TKIs Look to Solidify a Role Alongside T-DXd in the Second-Line HER2-Mutant NSCLC Setting

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

Limertinib for EGFR T790M+ NSCLC | Image Credit: © catalin – stock.adobe.com
January 17th 2025

Limertinib Wins Approval in China for EGFR T790M+ NSCLC

Alison Schram, MD
January 16th 2025

Zenocutuzumab Addresses High Unmet Need in NRG1-Positive NSCLC and Pancreatic Cancer